# US 2018/0021292 A1 · Methods of treating urea cycle disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021292 A1
- Document ID: US20180021292A1
- Status: Published application
- Kind: A1
- Application number: 15/699,188
- Filed: 2017-09-08
- Published: 2018-01-25
- Earliest claimed: 2013-10-14
- Assignees: Horizon Therapeutics, LLC
- Applicants: Horizon Therapeutics, LLC
- Inventors: Bruce SCHARSCHMIDT; Masoud MOKHTARANI
- Web page: https://patentgrep.com/patent/US20180021292A1

## CPC

- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/6812: {Assays for specific amino acids}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/708: Nitrogen metabolism, e.g. urea cycle
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method for determining or adjusting an effective dosage of a phenylacetic acid (PAA) prodrug to be administered to a subject with a urea cycle disorder, comprising:
calculating the body surface area (BSA) of the subject; and
administering an effective dosage of the PAA prodrug to the subject wherein the effective dosage of the PAA prodrug is a first dosage if the BSA is at or above 1.3 m2 or a second dosage if the BSA is below 1.3 m2, and wherein the second dosage is higher than the first dosage.

### Claim 22 (depends on 21)

The method of claim 21, wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject has previously been administered an initial dosage of an initial PAA prodrug.

### Claim 24 (depends on 23)

The method of claim 23, wherein the initial PAA prodrug is glyceryl tri-[4-phenylbutyrate].

### Claim 25 (depends on 23)

The method of claim 23, wherein the initial dosage of the glyceryl tri-[4-phenylbutyrate] is 5 to 12.4 g/m2/day.

### Claim 26 (depends on 25)

The method of claim 25, wherein the effective dosage of the PAA prodrug is 5.33 to 8.79 g/m2/day.

### Claim 27 (depends on 26)

The method of claim 26, wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].

### Claim 28 (depends on 25)

The method of claim 25, wherein the effective dosage of the PAA prodrug is 6.25 to 9.9 g/m2/day.

### Claim 29 (depends on 28)

The method of claim 28, wherein the PAA prodrug is glyceryl tri-[4-phenylbutyrate].

### Claim 30 (depends on 21)

The method of claim 21, wherein the subject is under the age of 12.

### Claim 31 (depends on 21)

The method of claim 21, wherein the PAA prodrug is administered orally.

### Claim 32

A method for treating a urea cycle disorder in a subject in need thereof wherein the subject has a body surface area (BSA) at or above 1.3 m2, comprising:
administering to the subject an effective dosage of glyceryl tri-[4-phenylbutyrate] of 5.33 to 8.79 g/m2/day.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject is under the age of 12.

### Claim 34 (depends on 32)

The method of claim 32, wherein the glyceryl tri-[4-phenylbutyrate] is administered orally.

### Claim 35 (depends on 32)

The method of claim 32, wherein the subject has not previously been administered a PAA prodrug.
